#DDHO2020 Emory Winship Debates and Didactics in Hematology and Oncology - Topics include breast, lung, colorectal, lymphoma, multiple myeloma and many other cancers
-
Madhav Dhodapkar, MBBS #DDHO2020
20:52
Overview of Immunology and Cancer presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Fuad El Rassi, MD #DDHO2020
31:22
How to diagnose and manage hemoglobinopathies in the community practice presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Bassel Nazha, MD, MPH #DDHO2020
26:38
Racial and ethnic disparities in clinical trials: Renal cell cancer presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Taofeek Owonikoko, MD, PhD., MSCR #DDHO2020
23:25
Small cell lung cancer: Proven and promising options presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Viraj Master, MD, PhD, FACS #DDHO2020
17:14
Update on management of adrenal cancer presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Susan O'Brien, MD #DDHO2020
16:28
Updates in CLL presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Fadlo Khuri, MD #DDHO2020
20:10
Targeted therapies for NSCLC: State of the art presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Brad Carthon, MD, PhD #DDHO2020
24:39
Updates in management of bladder cancer presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Martha Arellano, MD #DDHO2020
25:06
Use of MRD testing in AML presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
5 Live - Major conference takeways from experts in 5 minutes or less. Featuring new content from #ASCO20
-
Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
4:24
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
-
Ajay K. Nooka, MD, MPH, FACP; Emory Winship Cancer Institute 5Live #ASCO20
4:59
Key Insights on DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
-
Hope S. Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20
6:58
"Key Insights on Alpelisib + fulvestrant in PIK3CA-mutated HR+/HER2– advanced BC previously treated with CDK 4/6 inhibitor + aromatase inhibitor (AI): BYLieve study results "
-
Lindsey Roeker, MD Memorial Sloan-Kettering Cancer Center 5Live #ASCO20
3:55
Key Insights on Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
-
Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20
2:50
Key insights on IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
-
Andrew Evens, DO, MSc, FACP
6:16
Summary of Hodgkin lymphoma updates from SOHO 2019.
-
Sagar Lonial, MD Winship Cancer Institute of Emory University 5Live #ASCO20
5:00
Key Insights on Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with (RR) multiple myeloma refractory to (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).
-
David Siegel, MD, PhD
4:13
Summary of CAR T-cell Therapy. Updates from ASH 2019.
-
Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
5:36
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
